首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1672798

腎癌藥物市場：依療法、按藥理類別、按分銷管道、按地區

Kidney Cancer Drugs Market, By Therapy: Targeted Therapy, Immunotherapy, and Chemotherapy, By Pharmacological Class: Angiogenesis Inhibitors, mTOR Inhibitors, Cytokines, and Others, By Distribution Channel, By Geography

出版日期: 2025年02月14日 | 出版商:

Coherent Market Insights | 英文 173 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2025 年全球腎癌藥物市場規模估計為 73.1 億美元，預計到 2032 年將達到 110.7 億美元，2025 年至 2032 年的複合年成長率為 6.1%。

報告範圍		報告詳細資訊
基準年	2024	2025 年市場規模	73.1億美元
效能資料	從 2020 年到 2024 年	預測期	2025 至 2032 年
預測期：2025-2032年複合年成長率：	6.10%	2032 年價值預測	110.7億美元

數字。 2025 年各地區腎癌藥物市場佔有率（%）

藥物分析檢測是指以科學的技術和方法確認腎癌（又稱腎細胞癌）。腎癌正成為全球最常見的癌症之一。據估計，全球每年診斷出的新病例超過40萬例。與腎癌相關的危險因子包括吸煙、肥胖、遺傳因素和接觸某些毒素。早期腎癌可能不會引起任何症狀，但有些患者可能會出現尿液中帶血、腰部疼痛或腹部腫塊。治療方案包括局部疾病的部分或根治性切除術、針對晚期疾病的標靶治療和免疫治療。總體而言，由於發病率上升、患者獲得先進療法的機會改善以及強大的新藥管道等因素繼續支撐市場成長，全球腎癌藥物市場預計在未來幾年將大幅成長。

市場動態：

全球腎癌藥物市場受到全球腎細胞癌盛行率上升的推動。人口老化、肥胖率上升、職場毒素暴露增加等危險因子日益增多，導致了該病患病率的上升。此外，已開發國家患者獲得優質標靶治療和免疫療法的機會的改善也支持了市場的成長。同時，手術、放射療法和藥物療法結合的治療週期更長，意味著患者越來越依賴維持治療。雖然市場開發提供了有利可圖的成長機會，但關鍵藥物的專利到期和學名藥市場進入等因素可能會擾亂大型開發商的收益來源。此外，新興市場的高定價和可負擔性問題限制了其進入更廣泛的市場。然而，臨床試驗中針對各種疾病途徑的分子管線非常強大，為未來的市場擴張提供了潛力。

本研究的主要特點

本報告對全球腎癌藥物市場進行了詳細分析，並以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模（十億美元）和年複合成長率（CAGR%）。
它還強調了各個領域的潛在收益成長機會，並說明了該市場的引人注目的投資提案矩陣。
它還提供了對市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
它根據公司亮點、產品系列、關鍵亮點、績效和策略等參數，介紹了全球腎癌藥物市場的主要企業概況。
本報告的見解將使負責人和企業經營團隊能夠就未來產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。
全球腎癌藥物市場報告迎合了該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員將透過用於分析全球腎癌藥物市場的各種策略矩陣更輕鬆地做出決策。

公司簡介
- Pfizer Inc.
- 3D Systems
- Novartis AG
- Bristol-Myers Squibb Company
- Roche Holding AG（Genentech, Inc.）
- Bayer AG
- Exelixis, Inc.
- Merck &Co., Inc.
- Eisai Co., Ltd.
- Aveo Pharmaceuticals
- AstraZeneca PLC
- Ipsen Biopharmaceuticals, Inc.
- GlaxoSmithKline plc
- Abbott Laboratories Source
- Amgen Inc.
- Calithera Biosciences, Inc.
- Active Biotech
- Immatics Biotechnologies GmbH
- Karyopharm Therapeutics

第 10 章分析師建議

第 11 章參考文獻與調查方法

參考
調查方法

簡介目錄

Product Code: CMI2399

Global Kidney Cancer Drugs Market is estimated to be valued at USD 7.31 Bn in 2025 and is expected to reach USD 11.07 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.1% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 7.31 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	6.10%	2032 Value Projection:	USD 11.07 Bn

Figure. Kidney Cancer Drugs Market Share (%), By Region 2025

Pharmaceutical analytical testing refers to the use of scientific techniques and methods to establish kidney cancer, also known as renal cell carcinoma. It is becoming one of the most common cancers globally. According to estimates, over 400,000 new cases are diagnosed worldwide each year. Risk factors associated with kidney cancer include tobacco use, obesity, hereditary factors, and exposure to certain toxins. While early-stage disease may present no symptoms, some patients may see blood in urine, flank pain, or an abdominal mass. Treatment options range from partial or radical nephrectomy for localized disease to targeted therapies or immunotherapy for advanced cases. Overall, the global kidney cancer drugs market is expected to grow significantly in the coming years as factors such as rising incidence of disease, improving patient access to advanced treatments, and robust pipeline of novel drugs continue to support the market growth.

Market Dynamics:

The global kidney cancer drugs market is driven by the rising prevalence of renal cell carcinoma worldwide. Growing risk factors, such as increasing geriatric population, rising obesity rates, and greater exposure to toxins at the workplace, are contributing to the rising disease incidence. Additionally, improving patient access to premium targeted therapies and immunotherapies in developed nations are supporting the market growth. At the same time, lengthy duration of treatment involving combinations of surgery, radiotherapy, and drug regimens is keeping patients dependent on maintenance therapies for longer duration. While the market sees lucrative growth opportunities, factors such as patent expiration of major drugs and market entry of generics could hamper the revenue stream of leading developers. Moreover, high pricing and affordability issues in developing nations restrict broader market access. Nevertheless, robust pipeline of molecules under clinical trials targeting different disease pathways offers potential for market expansion in future.

Key Features of the Study:

This report provides in-depth analysis of the global kidney cancer drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global kidney cancer drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Merck & Co., Pfizer Inc., Novartis AG, Bayer AG, Amgen, F. Hoffmann-La Roche Ltd, and Eisai Co. Ltd
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global kidney cancer drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global kidney cancer drugs market

Detailed Segmentation-

By Therapy
- Targeted Therapy
- Immunotherapy
- Chemotherapy
By Pharmacological Class
- Angiogenesis Inhibitors
- mTOR Inhibitors
- Cytokines
- Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Pfizer Inc.
- Novartis AG
- Bristol-Myers Squibb Company
- Roche Holding AG (Genentech, Inc.)
- Bayer AG
- Exelixis, Inc.
- Merck & Co., Inc.
- Eisai Co., Ltd.
- Aveo Pharmaceuticals
- AstraZeneca PLC
- Ipsen Biopharmaceuticals, Inc.
- GlaxoSmithKline plc
- Abbott Laboratories Source
- Amgen Inc.
- Calithera Biosciences, Inc.
- Active Biotech
- Immatics Biotechnologies GmbH
- Karyopharm Therapeutics

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Therapy
- Market Snapshot, By Pharmacological Class
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Market Trends
Key Developments
Regulatory Scenario
Acquisitions and Partnerships Scenario
Funding and Investments
PEST Analysis
Porter's Analysis

4. Global Kidney Cancer Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the Market

5. Global Kidney Cancer Drugs Market, By Therapy, 2020 - 2032, (USD Bn)

Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Targeted Therapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Immunotherapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Chemotherapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Kidney Cancer Drugs Market, By Pharmacological Class, 2020 - 2032, (USD Bn)

Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Angiogenesis Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
mTOR Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Cytokines
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Kidney Cancer Drugs Market, By Distribution Channel, 2020 - 2032, (USD Bn)

Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Kidney Cancer Drugs Market, By Region, 2020 - 2032, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021-2032
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Pharmacological Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Pharmacological Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Pharmacological Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Pharmacological Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Pharmacological Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Pharmacological Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Company Profiles
- Pfizer Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- 3D Systems
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Novartis AG
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Bristol-Myers Squibb Company
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Roche Holding AG (Genentech, Inc.)
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Bayer AG
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Exelixis, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Merck & Co., Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Eisai Co., Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Aveo Pharmaceuticals
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- AstraZeneca PLC
- Ipsen Biopharmaceuticals, Inc.
- GlaxoSmithKline plc
- Abbott Laboratories Source
- Amgen Inc.
- Calithera Biosciences, Inc.
- Active Biotech
- Immatics Biotechnologies GmbH
- Karyopharm Therapeutics